Siltuximab
Siltuximab (INN) is an experimental antineoplastic (anti-cancer) drug and a monoclonal antibody. It binds to interleukin-6.[1] Siltuximab has been investigated for the treatment of metastatic renal cell cancer,[2] prostate cancer,[3] and Castleman's disease,[4] among other types of cancer.[5]
References
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ Rossi, J. -F.; Négrier, S.; James, N. D.; Kocak, I.; Hawkins, R.; Davis, H.; Prabhakar, U.; Qin, X. et al. (2010). "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer". British Journal of Cancer 103 (8): 1154–1162. doi:10.1038/sj.bjc.6605872. PMC 2967052. PMID 20808314. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2967052. edit
- ^ Karkera, J.; Steiner, H.; Li, W.; Skradski, V.; Moser, P. L.; Riethdorf, S.; Reddy, M.; Puchalski, T. et al. (2011). "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study". The Prostate 71 (13): 1455–1465. doi:10.1002/pros.21362. PMID 21321981. edit
- ^ Van Rhee, F.; Fayad, L.; Voorhees, P.; Furman, R.; Lonial, S.; Borghaei, H.; Sokol, L.; Crawford, J. et al. (2010). "Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease". Journal of Clinical Oncology 28 (23): 3701–3708. doi:10.1200/JCO.2009.27.2377. PMID 20625121. edit
- ^ ClinicalTrials.gov: Siltuximab
|
|
|
| Tumor ("-t(u[m])-") |
|
Human ("-tumu-")
|
|
|
|
Mouse ("-tumo-")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|